Overview

Injection of 99mTc-nanocolloid and ICG to Identify, Retrieve and Qualify TDLN in Early-stage NSCLC

Status:
Not yet recruiting
Trial end date:
2024-10-10
Target enrollment:
Participant gender:
Summary
The patient wil receive intra- or peritumoral injections of 99mTc-nanocolloid if malignancy is found during a navigation bronchoscopy. A SPECT/CT-scan will be made to image injections sites and sentinel lymph nodes (SLN). If surgery takes place to treat the lung cancer, ICG will be injected and fluorescent lymph nodes will be extensively assessed by a pathologist.
Phase:
N/A
Details
Lead Sponsor:
Radboud University Medical Center
Collaborators:
Johnson & Johnson
Philips Healthcare